Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MDM4 | O15151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30802567 | 0.93 | KMT2A (0.49) | KMT2AMDM4TP53EPHX2ITGB3 | |
| SCHEMBL12297754 | 0.93 | KMT2A (0.49) | KMT2AMDM4TP53EPHX2ITGB3 | |
| SCHEMBL29855073 | 0.93 | KMT2A (0.49) | KMT2AMDM4TP53EPHX2ITGB3 | |
| SCHEMBL31195699 | 0.93 | KMT2A (0.49) | KMT2AMDM4TP53EPHX2ITGB3 | |
| SCHEMBL18237209 | 0.93 | KMT2A (0.49) | KMT2AMDM4TP53EPHX2ITGB3 | |
| SCHEMBL18614206 | 0.90 | KMT2A (0.45) | KMT2AMDM4TP53EPHX2ITGB3 | |
| SCHEMBL32683646 | 0.90 | KMT2A (0.45) | KMT2AMDM4TP53EPHX2ITGB3 | |
| SCHEMBL20338593 | 0.90 | KMT2A (0.45) | KMT2AMDM4TP53EPHX2ITGB3 | |
| SCHEMBL12297763 | 0.89 | MDM2 (0.46) | KMT2AMDM4TP53EPHX2ITGB3 | |
| SCHEMBL25362437 | 0.88 | ITGB3 (0.45) | KMT2AMDM4TP53EPHX2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960349-B2 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2008-10-02 | — | — | US | disclosed |
| US-7417028-B2 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | KMT2A 2687/4885MDM4 4866/4885TP53 4145/4885 |
| US-20080242593-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, GIPR, IAPP | KMT2A 3518/4885MDM4 4725/4885TP53 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.